—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Grifols S.A. (GRF.MC) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GRF.MC, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GRF.MC on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Grifols S.A.

GRF.MC in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Grifols researches, produces and sells medicines made from human plasma, along with diagnostic testing equipment and hospital supplies. It runs through segments covering biopharma, diagnostics, bio supplies for other manufacturers, and hospital and laboratory services. Customers include hospitals, biotech firms and life-science researchers across the United States, Canada, Spain and other markets. It is based in Barcelona, Spain.
Where it sits in the stack
Grifols has no seat in our index and does not sit inside the AI build-out stack; it belongs to our Healthcare sector, in the Drug Manufacturers - General industry group.
Who it is priced against
The diary has not built a peer group for it; the comparison the market draws is with CSL, another large plasma-derived medicine maker.
Why Closelooknet tracks it
It carries a Closelooknet score, but with only one module scored the read is still being built; it holds no index seat and has not yet appeared in a diary edition or quote.
What the diary watches
The diary watches whether the shares stabilise against their recent slide below the 50- and 200-day averages, or move back toward the high they reached earlier in the year.

Grifols S.A. (GRF.MC) trades on the MC exchange in Spain.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 0.67%, annual · last 0.0667 EUR on 2026-06-30

Dividends and capital return

What GRF.MC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.0667 EUR per share · a 0.67% yield on the 2026-10-06 close 1 distribution, paid once a year 2026-10-06
  • Change on the year −45.1% against the prior twelve months prior twelve months 0.12 EUR per share
  • Last distribution 0.0667 EUR per share as the price series records it, within days of the ex-date 2026-06-30
  • By calendar year 2025: 0.12 EUR (partial) · 2026: 0.0667 EUR to date first distribution recorded in the three-year window: 2025-08-11

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Grifols S.A. (GRF.MC)?

Grifols S.A. trades as GRF.MC on the MC exchange (Spain) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is GRF.MC in a Closelooknet index?

Not currently — Grifols S.A. is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does GRF.MC trade against its moving averages?

Bullish stack, 200-day still turning: Trades +0.2% vs the 50-day and +1.5% vs the 200-day average, 18.4% below the 52-week high and +18.1% off the 52-week low; a golden cross printed 13 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Grifols S.A. compare with its peers?

Against its peer group (Drug Manufacturers - General), Grifols S.A. (GRF.MC) sits 18.4% below its 52-week high, 0.2% above its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Orion Oyj A (ORNAV.HE) is 3.4% below, Orion Oyj B (ORNBV.HE) is 3.8% below. Put any of them next to GRF.MC in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Grifols S.A. do?

Grifols researches, produces and sells medicines made from human plasma, along with diagnostic testing equipment and hospital supplies. It runs through segments covering biopharma, diagnostics, bio supplies for other manufacturers, and hospital and laboratory services. Customers include hospitals, biotech firms and life-science researchers across the United States, Canada, Spain and other markets. The diary has not built a peer group for it; the comparison the market draws is with CSL, another large plasma-derived medicine maker.

Where does Grifols S.A. sit in the AI build-out?

Grifols has no seat in our index and does not sit inside the AI build-out stack; it belongs to our Healthcare sector, in the Drug Manufacturers - General industry group. It carries a Closelooknet score, but with only one module scored the read is still being built; it holds no index seat and has not yet appeared in a diary edition or quote.

Does Grifols S.A. pay a dividend?

Grifols S.A. has paid 0.0667 EUR per share over the last twelve months, paid once a year, a trailing yield of 0.67% on the 2026-10-06 close; the last distribution recorded in the price series was 0.0667 EUR on 2026-06-30. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for GRF.MC, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.